Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada OKs SYN X' traumatic brain injury tests:

This article was originally published in Clinica

Executive Summary

SYN X Pharma has gained approval in Canada to sell serum-based test kits that measure what it claims are the first reliable biochemical markers of traumatic brain injury (TBI), such as Shaken Baby Syndrome. The Nexus Dx S-100 and Nexus Dx Neuron Specific Enolase (NSE) ELISA kits provide objective evidence of brain injury that will help physicians identify the Syndrome, allowing for child protection interventions, says the Toronto, Canada firm. SYN X is also developing a point-of-care TBI test.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT060946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel